Piper Sandler downgraded Livent to Underweight from Neutral with a price target of $15, down from $18. The downgrade reflects “recognition of the substantial deterioration” in global lithium markets, the analyst tells investors in a research note. The firm believes the market conditions now present will undermine any significant rebound in the pricing environment for at least the next few quarters, leading to further earnings erosion and estimate reduction. Piper cites the “problematic market environment” for the downgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LTHM:
- Livent price target lowered to $15 from $25 at JPMorgan
- Livent Announces Special Meeting Date to Vote on Pending Merger of Equals with Allkem; Form S-4 Registration Statement Declared Effective
- Allkem and Livent Receive All Required Regulatory Approvals Globally to Close Merger of Equals
- Livent, Allkem receive all regulatory approvals for merger
- Largest borrow rate increases among liquid names
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue